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Major Depressive Disorder (MDD) frequently emerges, and is substantially un-
recognized, throughout adolescence [3]. This transition from childhood to 
adulthood is a period of emotional instability, which leaves many susceptible to 
depression or other mental illnesses [2]. Depression is related to a range of 
negative emotional behaviors, from lingering sadness to serious suicidal 
inclinations. Recent studies have shown that 10-20% of youth will experience a 
major depressive episode by the end of adolescence [4]. Only two-thirds of 
depressed patients respond to standard anti-depressant medications. The limited 
effectiveness of current treatment methods is contributing to greater morbidity 
and public health costs [1]. In order to reduce this (and considering the high 
prevalence and severe consequences), there is an immediate need for advanced 
neurobiological treatments.   
  
Ketamine has recently been studied for its anti-depressant effects in adults with 
treatment-resistant depression (TRD). Recent data suggests that multiple 
infusions may have more sustained effects. The common anesthetic drug is 
associated with the N-methyl-D-aspartate glutamate receptor as an antagonist 
and is causing rapid anti-depressant effects even in those who failed to respond to 
previous treatments [1]. After administration of six intravenous ketamine 
infusions, adults with TRD have shown an overall response rate of 70.8%, and the 
duration of effects has lasted an average of 18 days [1]. The effects of ketamine 
has sparked ample interest among researchers, however, there are no reports on 
the effects of ketamine in adolescent TRD. 
Participants underwent six open-label intravenous ketamine (0.5 mg/kg) infusions 
over a two-week period. Initially, the dose was based on ideal weight. After the 
first five subjects, the dose was then based on actual weight. The primary response 
measure was the Children’s Depression Scale-Revised (CDRS-R). Response was 
defined as ≥ 50% decrease in CDRS-R scores from baseline to one day after the last 
infusion, as seen in the equation below.  
(Baseline CDRS – Exit CDRS) 
(Baseline CDRS – 17) 
The Montgomery-Asberg Depression Rating Scale (MADRS) was used to track 
depression severity throughout the study by measuring specific symptoms, as 
scored by the scale below [5]. MADRS scores were assessed at baseline, pre- and 
post- infusion, one day post-treatment, and at follow-ups. 
0-6 à normal/symptoms absent 
7-19 à mild depression 
20-34 à moderate depression 
34+ à severe depression 
Initially, participants were followed for six weeks post-treatment only if they met 
response criteria. After the first five subjects, all participants were monitored. 
To date, ten participants have completed the infusions. Of these, four participants have 
met criteria for response. All of the responders were in the second set of patients, for whom 
the dose was based on actual rather than ideal body weight. The overall response rate in 
adolescents (40%) is significantly lower than in adults (70.8%) [1]. Although the time-point 
of response is similar in both adolescents and adults, the duration of anti-depressant 
effects in adolescents (>42 days) is significantly different than in adults (~18 days) [1]. The 
average improvement seen in adolescent responders is 74%, with the strongest 
improvement in lassitude, reported sadness, inability to feel, and pessimistic thoughts. 
While most of the non-responders also showed a dramatic decrease in symptoms after the 
first infusion as measured by the MADRS, the symptoms continued to reappear by the 
following infusion. Non-responders showed slight improvement overall with an average of 
22% reduction in CDRS-R scores. Currently, the results show that the use of ketamine in 
adolescents with treatment-resistant depression has not yielded a response rate as high as 
adults, but the adolescents who do benefit from ketamine tend to experience more 
sustained anti-depressant effects. This could be due to the versatility of the growing 
adolescent brain allowing the ketamine to work more efficiently. The preliminary results 
also suggest that actual-weight dosing, versus ideal-weight dosing, may be the superior 
ketamine regimen for adolescents with severe depression. The anti-depressant effects of 
ketamine could provide a massive leap forward in public health and the struggle to find 
advanced neurobiological treatments, however, more studies are required.  
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INTRODUCTION RESULTS 
•  Examine efficacy and durability of anti-depressant effects in an adolescent 
TRD sample 
•  Identify what specific symptoms of depression contributed most to the 
improvement 
•  Establish the superior dosing regimen for maximization of effects 
•  Compare overall response rates and duration of anti-depressant effects in 
adolescents to adults 
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Figure 1. Change in Children’s Depression Rating Scale-Revised (CDRS-R) 
scores from baseline to exit for all participants. These scores were used in the 
CDRS-R equation to determine participants as a responder or non-responder. 
Those who met response criteria with ≥ 50% change in scores were 
participants 6, 7, 8, and 10. This creates an overall response rate of 40%.  
Figure 2. Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores for 
responders and non-responders throughout study. The figure depicts changes in 
depression severity from the ketamine infusions and follow-up phase. The time-point of 
response appears to be immediate. The first five participants were not monitored after the 
infusions, as they were non-responders, until the protocol was changed to follow-up with 
all participants. The follow-up phase for non-responders on the figure is represented by 
the one non-responder after the protocol change (participant 9). The follow-up phase for 
responders is represented by three participants who have completed the follow-ups to 
date, as well as one participant who completed the 6 month follow-up.    
Figure 3. Improvement of depression severity in responders by specific 
symptoms of the Montgomery-Asberg Depression Rating Scale (MADRS). Those 
who met response criteria by the CDRS-R were examined for specific 
improvement in treatment-resistant depression. The figure depicts large 
improvement in lassitude, reported sadness, inability to feel, and pessimistic 
thoughts from baseline to exit.  
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